content: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date of Report (Date of earliest event reported)       APRIL 19, 1996
  
                                ENZON, INC.
  
            (Exact  name  of  registrant  as  specified in its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  
  
  
  
  
  
  
  <PAGE>
  ITEM 5.  OTHER EVENTS
  
            On April 19, 1996, the Board of Directors (the "Board") of Enzon,
  Inc. ("Enzon" or the "Company") elected Randy H. Thurman as Chairman of the
  Company's Board of Directors.
  
            Mr. Thurman has been a director of Enzon since 1993.  He replaces
  Dr. Abraham Abuchowski, a co-founder and/or director of Enzon since 1983.
  
            Mr.  Thurman  most  recently  was  Chairman  and Chief  Executive
  Officer  of  Corning  Life Sciences, a diversified health services  company
  specializing in contract  pharmaceutical research and commercial laboratory
  testing.  Previously, Mr. Thurman  was  President  of  Rhone-Poulenc  Rorer
  Pharmaceuticals.   He  is  also  the  founder  and  Chairman of Health Care
  Strategies 2000, a global healthcare consulting company  focusing on health
  care strategy.
  
            Mr.  Thurman  will  serve  in  a  non-executive role and  provide
  strategic  guidance  and  assist  in  building relationships  with  leading
  companies and institutions.
  
            The  Company  also  formed a Research  and  Development  Steering
  Committee which will direct the  overall  Research and Development strategy
  reporting to Mr. Tombros.  Joining Mr. Tombros on the Steering Committee is
  Rosina B. Dixon, M.D., who previously held senior positions in Research and
  Development with Ciba-Geigy and Schering-Plough.   Dr.  Dixon is a director
  of  Enzon.   Richard Cooper, M.D., Chairman of Enzon's Scientific  Advisory
  Committee, Director  of  the  Medical  College  of  Wisconsin Health Policy
  Institute and retired Dean of the Medical College of  Wisconsin  will  also
  serve  on the Steering Committee, along with Dr. Robert Shorr, Enzon's vice
  president of Research and Development.  Dr. Abuchowski has relinquished all
  of his responsibilities  as  an employee of Enzon and has resigned from the
  Board of Directors.
  
            On April 19, the Company  received  an inquiry from Nasdaq Market
  Surveillance  regarding market activity in the company's  common  stock  on
  Friday, April 19.   The  company has issued a press release stating that it
  knows of no other corporate  developments, aside from the matters involving
  Dr. Abuchowski's parting with  the Company, which would explain the trading
  activities in the company's common stock on Friday, April 19.
  
  
  
  <PAGE>
                              SIGNATURES
  
  
       Pursuant to the requirements  of  the Securities Exchange Act of 1934,
  
  the Registrant has duly caused this report  to  be  signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  
  
  
  Dated:  April 23, 1996
  
  
  
  
                                                 ENZON, INC.
                                               (Registrant)
  
                                     By:   /S/JOHN A. CARUSO
                                           John A. Caruso
                                           Vice President,
                                           Business Development and
                                           General Counsel
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3928}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96550174"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date of Report (Date of earliest event reported)       APRIL 19, 1996
  
                                ENZON, INC.
  
            (Exact  name  of  registrant  as  specified in its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  ITEM 5.  OTHER EVENTS
  
            On April 19, 1996, the Board of Directors (the "Board") of Enzon,
  Inc. ("Enzon" or the "Company") elected Randy H. Thurman as Chairman of the
  Company's Board of Directors.
  
            Mr. Thurman has been a director of Enzon since 1993.  He replaces
  Dr. Abraham Abuchowski, a co-founder and/or director of Enzon since 1983.
  
            Mr.  Thurman  most  recently  was  Chairman  and Chief  Executive
  Officer  of  Corning  Life Sciences, a diversified health services  company
  specializing in contract  pharmaceutical research and commercial laboratory
  testing.  Previously, Mr. Thurman  was  President  of  Rhone-Poulenc  Rorer
  Pharmaceuticals.   He  is  also  the  founder  and  Chairman of Health Care
  Strategies 2000, a global healthcare consulting company  focusing on health
  care strategy.
  
            Mr.  Thurman  will  serve  in  a  non-executive role and  provide
  strategic  guidance  and  assist  in  building relationships  with  leading
  companies and institutions.
  
            The  Company  also  formed a Research  and  Development  Steering
  Committee which will direct the  overall  Research and Development strategy
  reporting to Mr. Tombros.  Joining Mr. Tombros on the Steering Committee is
  Rosina B. Dixon, M.D., who previously held senior positions in Research and
  Development with Ciba-Geigy and Schering-Plough.   Dr.  Dixon is a director
  of  Enzon.   Richard Cooper, M.D., Chairman of Enzon's Scientific  Advisory
  Committee, Director  of  the  Medical  College  of  Wisconsin Health Policy
  Institute and retired Dean of the Medical College of  Wisconsin  will  also
  serve  on the Steering Committee, along with Dr. Robert Shorr, Enzon's vice
  president of Research and Development.  Dr. Abuchowski has relinquished all
  of his responsibilities  as  an employee of Enzon and has resigned from the
  Board of Directors.
  
            On April 19, the Company  received  an inquiry from Nasdaq Market
  Surveillance  regarding market activity in the company's  common  stock  on
  Friday, April 19.   The  company has issued a press release stating that it
  knows of no other corporate  developments, aside from the matters involving
  Dr. Abuchowski's parting with  the Company, which would explain the trading
  activities in the company's common stock on Friday, April 19.
  SIGNATURES
  
       Pursuant to the requirements  of  the Securities Exchange Act of 1934,
  
  the Registrant has duly caused this report  to  be  signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  Dated:  April 23, 1996
  
                                                 ENZON, INC.
                                               (Registrant)
  
                                     By:   /S/JOHN A. CARUSO
                                           John A. Caruso
                                           Vice President,
                                           Business Development and
                                           General Counsel